XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
05/08/26	₩1,184.00	+0.85%	25,651
04/08/26	₩1,174.00	+6.24%	45,881
03/08/26	₩1,105.00	+1.47%	40,714
31/07/26	₩1,089.00	-0.55%	35,838
30/07/26	₩1,095.00	+0.09%	80,623

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 05/08/2026			5-day change	1st Jan Change
1,184.00 ^KRW	+0.85%		+8.23%	-28.72%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
21/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	20.48B 14.39M 12.46M 11.62M 10.69M 20.17M 1.37B 20.4M 137M 53.58M 685M 54.04M 52.85M 2.27B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	19.06B 13.39M 11.6M 10.81M 9.94M 18.77M 1.27B 18.98M 127M 49.87M 637M 50.3M 49.19M 2.11B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
21/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+0.85%
1 week	+8.23%
Current month	+8.72%
1 month	+0.25%
3 months	-26.09%
6 months	-38.08%
Current year	-28.72%

Xcell Therapeutics Inc. Share Price

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news : Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,063	1,198
1 month	1,009	1,279
Current year	1,009	2,050
1 year	1,009	4,075
3 years	1,009	12,900
5 years	1,009	12,900
10 years	1,009	12,900

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+0.85%	+8.23%	-62.23%	-	14.39M
ELI LILLY AND COMPANY	+4.86%	-3.32%	+52.73%	+160.26%	1,043B
JOHNSON & JOHNSON	+1.04%	-2.99%	+50.87%	+52.38%	621B
ABBVIE INC.	+0.98%	-6.49%	+24.00%	+66.66%	435B
ROCHE HOLDING AG	+1.96%	+0.83%	+42.80%	+37.60%	361B
NOVARTIS AG	-0.11%	-4.07%	+30.37%	+39.73%	293B
ASTRAZENECA PLC	+2.52%	-8.36%	+7.27%	+10.32%	251B
AMGEN INC.	+4.57%	+5.21%	+35.91%	+67.64%	220B
NOVO NORDISK A/S	-4.32%	-12.94%	-3.79%	-44.56%	201B
GILEAD SCIENCES, INC.	-2.58%	-0.73%	+17.16%	+67.46%	164B
Average	+0.56%	-2.62%	+19.51%	+50.83%	358.92B
Weighted average by Cap.	+0.77%	-3.79%	+37.10%	+76.20%

	2024	2025
Net sales	1.93B 1.36M 1.18M 1.1M 1.01M 1.91M 129M 1.93M 12.9M 5.06M 64.67M 5.11M 4.99M 214M	1.95B 1.37M 1.19M 1.11M 1.02M 1.92M 130M 1.94M 12.99M 5.1M 65.16M 5.14M 5.03M 216M
Net income	-9.54B -6.71M -5.81M -5.41M -4.98M -9.4M -638M -9.51M -63.63M -24.97M -319M -25.19M -24.63M -1.06B	-10.93B -7.68M -6.65M -6.2M -5.7M -10.76M -730M -10.88M -72.85M -28.59M -365M -28.84M -28.2M -1.21B
Net Debt	-3.1B -2.18M -1.89M -1.76M -1.62M -3.05M -207M -3.09M -20.67M -8.11M -104M -8.18M -8M -343M	-1.42B -997K -864K -805K -741K -1.4M -94.84M -1.41M -9.46M -3.71M -47.46M -3.75M -3.66M -157M